- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Immunovia AB: Immunovia Publishes Interim Report for January-March 2026 | 151 | GlobeNewswire (Europe) | Highlights January-March 2026Net sales and operating results for Q1 2026 in line with expectations: Net sales of 374 KSEK (139) for the period included royalties and revenues from PancreaSure tests.... ► Artikel lesen | |
| 24.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2025 | 293 | GlobeNewswire (Europe) | Highlights October-December 2025Net sales and operating results for Q4 2025 in line with expectations: Net sales of 354 KSEK for the period (455) largely reflected royalty revenue. Operating loss was... ► Artikel lesen | |
| 20.01. | Immunovia AB: The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting | 142 | GlobeNewswire (Europe) | Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary... ► Artikel lesen | |
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 216 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 375 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11.25 | Immunovia AB Q3 Loss Decreases | 2 | RTTNews | ||
| 26.11.25 | Immunovia: Strategiewechsel und Aktiensprung nach Q3-Zahlen | 3 | Investing.com Deutsch | ||
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 264 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 26.11.25 | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 286 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen | |
| 03.10.25 | Immunovia AB: Immunovia publishes information document regarding rights issue | 526 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 01.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 690 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| 29.09.25 | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 445 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 22.09.25 | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 624 | GlobeNewswire (Europe) | CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09.25 | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 313 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09.25 | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 319 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09.25 | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 315 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08.25 | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 263 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08.25 | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 559 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08.25 | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 259 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen | |
| 14.05.25 | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 343 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 21,380 | -13,65 % | Earnings Preview: Nebius, Hims & Hers, Cisco & Co. Welche Zahlen diese Woche spannend werden! | © Foto: Yuki Iwamura - AP/dpa +++ dpa-Bildfunk +++Diese in den kommenden Tagen (KW20) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell... ► Artikel lesen | |
| BECTON DICKINSON | 125,65 | +3,33 % | Bactiguard Holding AB: Bactiguard and BD strengthen global partnership expanding access to Foley catheters designed to reduce infection risk for patients worldwide | Bactiguard Holding AB (publ) today announces an update to its long standing collaboration with license partner BD (Becton, Dickinson & Company), a leading global medical technology company, through... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,180 | +13,46 % | Ryman Healthcare Slid To Loss In H1 | WELLINGTON (dpa-AFX) - Ryman Healthcare Ltd. (RYM.NZ), a retirement village and rest home operator, on Thursday reported loss in the first half compared with the previous year. For the half... ► Artikel lesen | |
| SOLENO THERAPEUTICS | 44,730 | -0,51 % | SOLENO THERAPEUTICS INC - 10-Q, Quarterly Report | ||
| SIENNA SENIOR LIVING | 14,000 | 0,00 % | Sienna Senior Living verfehlt Umsatzprognose für Q1 2026 - Aktie gibt nach | ||
| NIAGEN BIOSCIENCE | 3,380 | 0,00 % | Niagen Bioscience stock price target lowered to $11 by H.C. Wainwright | ||
| MICROPORT SCIENTIFIC | 0,930 | -2,62 % | MICROPORT (00853): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | ||
| EXTENDICARE | 19,700 | +1,03 % | Extendicare Inc.: Extendicare Announces 2026 First Quarter Results | MARKHAM, Ontario, May 07, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) today reported results for the three months ended March 31, 2026. First Quarter 2026... ► Artikel lesen | |
| VERADIGM | 7,350 | -100,00 % | Veradigm Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| NATIONAL HEALTHCARE CORPORATION | 158,00 | +0,64 % | National HealthCare Corp. Q1 Profit Advances | ||
| UNIPHAR | 4,185 | -2,45 % | Uniphar PLC - AGM Results | ||
| HANGZHOU TIGERMED CONSULTING | 4,060 | -0,49 % | TIGERMED (03347): INSIDE INFORMATION INVESTIGATION AGAINST DIRECTORS AND CONTROLLING SHAREHOLDERS | ||
| AESTHETIC MEDICAL INTERNATIONAL | 0,032 | 0,00 % | Aesthetic Medical International Holdings Group Ltd - 20-F, Annual and transition report of foreign private issuers | ||
| FRESENIUS | 39,520 | -0,90 % | EQS-News: Fresenius SE & Co. KGaA: Exzellenter Jahresauftakt: Fresenius zeigt anhaltend operative Stärke und Resilienz; Ausblick bestätigt | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Quartalsergebnis
Exzellenter Jahresauftakt: Fresenius zeigt anhaltend operative Stärke und Resilienz; Ausblick bestätigt (News... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 33,900 | +0,98 % | Siemens Healthineers: Aktie rutscht nach enttäuschenden Zahlen ab - Anleger reagieren enttäuscht | Schwache Quartalszahlen und anhaltende Probleme in China setzen Siemens Healthineers weiter unter Druck. Die Aktie verliert deutlich, während der Medizintechnikkonzern seine Prognose für das laufende... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.